Researchers unzip MRSA and discover route for vaccine
University of Rochester Medical Center orthopaedic scientists are a step closer to developing a vaccine to prevent life-threatening methicillin-resistant Staphylococcus aureus (MRSA) infections following bone and joint surgery.
Other MRSA vaccine research has failed to produce a viable option for patients because of the inability to identify an agent that can break through the deadly bacteria's unique armor. Most other research has targeted the surface of the bacteria, but the URMC team discovered an antibody that reaches beyond the microbe's surface and can stop the MRSA bacteria from growing, at least in mice and in cell cultures.
The Orthopaedic Research Society invited URMC researchers to present their findings at the ORS annual meeting in Long Beach, Calif. The team is led by Edward M. Schwarz, Ph.D., professor of Orthopaedics and associate director of the URMC Center for Musculoskeletal Research. John Varrone, a second-year graduate student in Schwarz's lab, will discuss the data at ORS and the ongoing search for attractive molecular candidates for use in a vaccine.
Management of MRSA infections due to bone and joint surgery is very challenging, Schwarz said, and therefore a vaccine to prevent the infection is badly needed.
It is difficult to pin down the source of most post-surgical MRSA infections, but the health and financial consequences are severe. Hospital stays can last up to six months. Standard treatment includes removing the MRSA-colonized prosthetic joint replacement, then an extensive washing and draining of the infected area in an attempt to clear out all bacteria before it seeds in nearby tissue and bone. Antibiotic spacers are usually placed near the joint for six to eight weeks.
A second joint replacement is an option only if the antibiotic-spacer treatment is successful and the health of the patient remains stable. However, the re-infection rate is very high (40 to 50 percent) and remains a risk for months or even years after the initial assault. In some cases the patient never fully regains the use of the infected joint, said Regis O'Keefe, chief of Orthopaedics at URMC and an expert in the treatment of MRSA.
"It's essential that we have mechanisms in place to prevent this awful infection," O'Keefe said. "We are very excited about our vaccine research. It'll have a phenomenal impact on individuals locally and across the country if we are successful."
Schwarz, Varrone, and colleagues hypothesized that the best way to attack staph aureus was to target the glucosaminidase (Gmd) protein contained in the deadly bug. Gmd is known to act as a zipper on the bacteria, opening the impenetrable armor (cell wall) during cell division. In the absence of Gmd, staph aureus cannot replicate efficiently, dramatically reducing its ability to cause infections. Thus, if they could find an agent that inhibits bacterial growth and prevents the cell wall from closing during binary fission, Schwarz reasoned, perhaps the bacteria itself could be destroyed.
The abstract presented at ORS describes two key findings. First, the Schwarz lab discovered four anti-Gmd monoclonal antibodies that disrupt the growth of MRSA bacteria in cell cultures, by breaking the zipper and preventing cell division. The team also demonstrated exactly how the antibody works. Since MRSA is inclined to grow rapidly, as single cells, they sought an antigen that forced the bacteria cells to clump. Electron microscopy images of the bacteria exposed to the anti-Gmd antibodies show evidence of exploding staph; however, additional research is being done to confirm this mechanism of action.
Second, researchers demonstrated that when mice were infused with the anti-Gmd antibody, and then exposed to MRSA, only about half of the mice developed the infection. As expected, Schwarz said, protection was dependent upon vaccine dose, with the lowest dose offering the least amount of protection.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
